Obesity treatments represent a huge market opportunity for drugmakers. Some analysts have projected annual sales as high as $50 billion for effective treatments, and developers have recently been sprinting to capitalize.
The race has been focused on drugs in Wegovy and Mounjaro’s class. These medicines, which act on hormones involved in insulin secretion, began as diabetes treatments because of their ability to control blood sugar. But they’ve shown a striking ability to lower weight, too, leading several drugmakers to advance competing programs in lockstep.
